ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
6,040.04
1.10%
US Tech 100
21,198.40
1.36%
Dow Jones
43,297.03
0.91%
Brent Oil
73.285
0.00%
Bitcoin
99,000.90
0.33%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE

  6. Arcus Biosciences Inc (RCUS) Quote

Arcus Biosciences Inc

Arcus Biosciences Inc (RCUS)

NYSE
15.91
-0.05
(-0.31%)
Closed December 25 4:00PM
Delayed by 15 minutes
15.91
0.00
(0.00%)
After Hours: 5:04PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
15.91
Bid
-
Ask
-
Volume
157,238
15.46 Day's Range 16.00
13.52 52 Week Range 20.31
Market Cap
1.456B
Previous Close
15.96
Open
16.00
Last Trade
32385
@
15.91
Last Trade Time
Financial Volume
$ 2,497,018
VWAP
15.8805
Average Volume (3m)
778,082
Shares Outstanding
91,511,609
Dividend Yield
-
PE Ratio
-4.74
Earnings Per Share (EPS)
-3.35
Revenue
117M
Net Profit
-307M

About Arcus Biosciences Inc

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule... Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.arcusbio.com
Headquarters
Camden, Delaware, USA
Founded
-
Arcus Biosciences Inc is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker RCUS. The last closing price for Arcus Biosciences was $15.96. Over the last year, Arcus Biosciences shares have traded in a share price range of $ 13.52 to $ 20.31.

Arcus Biosciences currently has 91,511,609 shares outstanding. The market capitalization of Arcus Biosciences is $1.46 billion. Arcus Biosciences has a price to earnings ratio (PE ratio) of -4.74.

Ask ADVFN Intelligence (AI)

RCUS Latest News

More News

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today...

13 hours ago
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

December 20 2024
Edgar (US Regulatory)

Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that...

December 19 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

December 17 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

December 17 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

December 17 2024
Edgar (US Regulatory)

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today...

December 10 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

December 04 2024
Edgar (US Regulatory)

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today...

December 03 2024
Business Wire

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that...

November 19 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.335-2.062172976316.24516.4414.77596406915.58842265CS
41.6211.336599020314.2918.0914.2974480416.30203024CS
120.664.3278688524615.2518.9814.1577808216.50407046CS
26-0.59-3.5757575757616.518.9813.5267574116.17522739CS
52-2.49-13.532608695718.420.3113.5272772116.58104504CS
156-29.09-64.64444444444545.912.9586824321.52358706CS
2605.9960.38306451619.9249.18.5574888223.78182795CS

RCUS - Frequently Asked Questions (FAQ)

What is the current Arcus Biosciences share price?
The current share price of Arcus Biosciences is $ 15.91
How many Arcus Biosciences shares are in issue?
Arcus Biosciences has 91,511,609 shares in issue
What is the market cap of Arcus Biosciences?
The market capitalisation of Arcus Biosciences is USD 1.46B
What is the 1 year trading range for Arcus Biosciences share price?
Arcus Biosciences has traded in the range of $ 13.52 to $ 20.31 during the past year
What is the PE ratio of Arcus Biosciences?
The price to earnings ratio of Arcus Biosciences is -4.74
What is the cash to sales ratio of Arcus Biosciences?
The cash to sales ratio of Arcus Biosciences is 12.44
What is the reporting currency for Arcus Biosciences?
Arcus Biosciences reports financial results in USD
What is the latest annual turnover for Arcus Biosciences?
The latest annual turnover of Arcus Biosciences is USD 117M
What is the latest annual profit for Arcus Biosciences?
The latest annual profit of Arcus Biosciences is USD -307M
What is the registered address of Arcus Biosciences?
The registered address for Arcus Biosciences is 2140 S DUPONT HWY, KENT, CAMDEN, DELAWARE, 19934
What is the Arcus Biosciences website address?
The website address for Arcus Biosciences is www.arcusbio.com
Which industry sector does Arcus Biosciences operate in?
Arcus Biosciences operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MPLNChurchill Capital Corp III
$ 12.24
(94.90%)
2.11M
NEUENeuehealth Inc
$ 7.54
(74.94%)
780.07k
SESSES AI Corporation
$ 0.71
(36.33%)
48.69M
KOREKORE Group Holdings Inc
$ 1.88
(27.89%)
297.19k
EVTLVertical Aerospace Ltd
$ 8.96
(20.75%)
286.9k
VNCEVince Holding Corp
$ 4.00
(-20.00%)
409.69k
DNMRDanimer Scientific Inc
$ 3.23
(-15.22%)
123.46k
CDR-BCedar Realty Trust Inc
$ 14.0301
(-10.34%)
8.45k
WSO.BWatsco Inc
$ 489.70
(-8.47%)
11
MOGUMOGU Inc
$ 2.18
(-8.02%)
3.55k
QBTSD Wave Quantum Inc
$ 7.95
(-2.45%)
51.47M
BBAIBigBear ai Holdings Inc
$ 3.73
(16.93%)
49.68M
SESSES AI Corporation
$ 0.71
(36.33%)
48.69M
ACHRArcher Aviation Inc
$ 10.80
(15.14%)
48.49M
FFord Motor Company
$ 10.02
(1.21%)
29.1M

RCUS Discussion

View Posts
Monksdream Monksdream 3 months ago
RCUS a buy under $14
👍️0
PennyWorld PennyWorld 1 year ago
https://seekingalpha.com/news/4005456-roche-send-anti-tigit-developers-higher-after-cancer-drug-data?ref=biztoc.com
👍️0
conix conix 3 years ago
Biotechs are starting to react to news...finally.
👍️0
dinogreeves dinogreeves 5 years ago
The stock didn't react as well as expected with the partnership, but it did hi almost my price target. This is a partnership 200 million equity investment and 175 million up front payment, which. implies no offering on the table. Makes you wonder why the stock is down, guess people were expecting a buyout. Some of these people are so lame, unbelievable.
👍️0
lovetc lovetc 5 years ago
Also in the DEF 14.....didnt see any information regarding Gilead....
👍️0
lovetc lovetc 5 years ago
shorted some and bought some put at $31 last Friday....Also today when it reached $30 I short.....I find no reason not to short above $30 lol....It will be $18 soon since the Volumn start declined....
👍️0
dinogreeves dinogreeves 5 years ago
RCUS will likely hit 40 this week and if it does that could essentially mean that there is buyout looming from GI*LD. Someone is buying heavy between 27-29 dollars, obviously they don't want it dip more than 26-27 dollars, it could be a number of reasons that is beyond any retails control.
👍️0
dinogreeves dinogreeves 5 years ago
Bought another 1000 shares on that dip, going to wait this one.
👍️0
dinogreeves dinogreeves 5 years ago
Possible huge asset buy, or outright buyout coming from GILD or even a partnership.
👍️0
dinogreeves dinogreeves 5 years ago
RCUS getting ready to pop to 33-35 dollars.
👍️0
dinogreeves dinogreeves 5 years ago
This is my letter to the shorts with margin account


That is where dummies like you are mistaken. If GILD places anywhere close to that dollar amount this stock jumps over triple digits in less then 2 hours and if there is buyout it won't even let you blink, just one share will it to the buyout price. If GOOGLE has 17% stake on this company and GILD is looking to either buy or take a stake, there must be something that you and I are not aware of the current directors sold their pervious company to Bristol for 1.5 billion dollars. There is more here than meets the eye. I am taking my chance because if no balls no glory and when that happens short margin account will be vaporized.


https://markets.businessinsider.com/news/stocks/arcus-biosciences-stock-spikes-reports-gilead-investing-cancer-drug-biotech-2020-4-1029100118
👍️0
dinogreeves dinogreeves 5 years ago
If this happens the stock will shoot up to over $200 dollars in an instant. Only if that happens.



https://markets.businessinsider.com/news/stocks/arcus-biosciences-stock-spikes-reports-gilead-investing-cancer-drug-biotech-2020-4-1029100118
👍️0
dinogreeves dinogreeves 5 years ago
News could come from GI*LD that there is a buyout. Watch for news.
👍️0

Your Recent History

NYSE
RCUS
Arcus Biosciences
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads